Carl Goldfischer, MD, is an Investment Partner and Managing Director of Bay City Capital, serving as a member of the board of directors and executive committee, and has been with the firm since December 2000. His background includes extensive public and private investment and transaction work, as well as clinical trial development knowledge. Prior to joining Bay City Capital, Dr. Goldfischer was, until mid-2000, Chief Financial Officer of ImClone Systems where he oversaw financial operations and strategic planning. Previously, he was a Research Analyst with the Reliance Insurance Company, helping to establish its portfolio and presence in the health care investment community. Dr. Goldfischer serves on the board of directors of numerous companies, including: BrainCells, EnteroMedics, Epizyme, MAP Pharmaceuticals, Metabolex, Poniard Pharmaceuticals, and PTC Therapeutics. He received an MD with honors in Scientific Research from Albert Einstein College of Medicine, and a BA from Sarah Lawrence College.